product
Povetacicept
Povetacicept is a Vertex Pharmaceuticals drug that blocks two immune signalling proteins, BAFF and APRIL, involved in B cell-driven autoimmune diseases.[1] Vertex has asked the FDA for accelerated approval in adults with IgA nephropathy, a kidney disease, and the application is under priority review with a target action date of 30 November 2026.[2][3] The filing rests on an interim analysis of the ongoing phase 3 RAINIER trial.[3]
Key facts
Povetacicept is a Vertex Pharmaceuticals drug that inhibits two cytokines, BAFF and APRIL, which play key roles in B cell-driven autoimmune diseases.[1] Its first target is IgA nephropathy, a kidney disease. For background on kidney disease, see chronic kidney disease explained.[2]
This page is not medical advice. Anyone with kidney disease should talk to their nephrologist.
The FDA application
By 31 March 2026 Vertex had completed a rolling application for accelerated approval of povetacicept in adults with IgA nephropathy. It used a priority review voucher to shorten the review.[2] As of November 2026 the application was under priority review, with a target action date of 30 November 2026.[3] Vertex said that, if approved, povetacicept would be the first commercial therapy in its kidney franchise.[4] For how accelerated approval fits into the process, see how FDA drug approval works.
The evidence
The application is supported by a pre-specified week-36 interim analysis of the phase 3 RAINIER trial, which is still running.[3]
Outside the US and beyond IgA nephropathy
Povetacicept was also under review for accelerated approval in IgA nephropathy in Saudi Arabia as of November 2026.[5] Vertex is testing it in primary membranous nephropathy, where the FDA has granted Fast Track and Orphan Drug designations. It is also testing it in generalized myasthenia gravis, with phase 2 results expected in the first half of 2027.[6]
What to watch
The next milestone is the FDA’s action, due by 30 November 2026.[3]
Read next
Health in 2026: a crash course
How drugs are tested and approved, who regulates them, and where to start on cholesterol, diabetes, dementia, ALS and cancer screening.
Questions readers ask
What is povetacicept?
A Vertex Pharmaceuticals drug that inhibits BAFF and APRIL, two cytokines that play key roles in B cell-driven autoimmune diseases.[1]
What is it being reviewed for?
Accelerated approval in adults with IgA nephropathy. Vertex completed its application by 31 March 2026 and used a priority review voucher to shorten the review.[2]
When will the FDA decide?
The target action date is 30 November 2026.[3]
What evidence supports the application?
A pre-specified week-36 interim analysis of the ongoing phase 3 RAINIER trial.[3]
Is it being tested for other diseases?
Yes. Vertex is testing it in primary membranous nephropathy, where it has FDA Fast Track and Orphan Drug designations, and in generalized myasthenia gravis, with phase 2 results expected in the first half of 2027.[6]
Sources
· 6 claims from 1 publisher
Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.
- [1]
Vertex describes povetacicept as a dual inhibitor of BAFF and APRIL, two cytokines involved in B cell-driven autoimmune diseases. confirmedas of 2026-11-02
- Vertex Pharmaceuticals third quarter 2026 results press release (Form 8-K exhibit) · Vertex Pharmaceuticals (SEC filing) · Primary source · 2026-11-02 (retrieved 2026-11-14)
- [2]
By 31 March 2026 Vertex had completed its rolling Biologics License Application for potential accelerated approval of povetacicept in adults with IgA nephropathy, using a priority review voucher to shorten the review. confirmedas of 2026-03-31
- Vertex Pharmaceuticals Form 8-K on completing the povetacicept BLA submission · Vertex Pharmaceuticals (SEC filing) · Primary source · 2026-03-31 (retrieved 2026-11-14)
- Vertex Pharmaceuticals Form 8-K on completing the povetacicept BLA submission · Vertex Pharmaceuticals (SEC filing) · Primary source · 2026-03-31 (retrieved 2026-11-14)
- [3]
As of November 2026 the povetacicept application for accelerated approval in IgA nephropathy was under FDA priority review with a target action date of 30 November 2026, supported by a pre-specified week-36 interim analysis of the ongoing phase 3 RAINIER trial. confirmedas of 2026-11-02
- Vertex Pharmaceuticals third quarter 2026 results press release (Form 8-K exhibit) · Vertex Pharmaceuticals (SEC filing) · Primary source · 2026-11-02 (retrieved 2026-11-14)
- Vertex Pharmaceuticals third quarter 2026 results press release (Form 8-K exhibit) · Vertex Pharmaceuticals (SEC filing) · Primary source · 2026-11-02 (retrieved 2026-11-14)
- [4]
Vertex said that, if approved, povetacicept would be the first commercial therapy in its nephrology franchise. confirmedas of 2026-11-02
- Vertex Pharmaceuticals third quarter 2026 results press release (Form 8-K exhibit) · Vertex Pharmaceuticals (SEC filing) · Primary source · 2026-11-02 (retrieved 2026-11-14)
- [5]
Povetacicept was also under review for accelerated approval in IgA nephropathy in Saudi Arabia as of November 2026. confirmedas of 2026-11-02
- Vertex Pharmaceuticals third quarter 2026 results press release (Form 8-K exhibit) · Vertex Pharmaceuticals (SEC filing) · Primary source · 2026-11-02 (retrieved 2026-11-14)
- [6]
Vertex is also testing povetacicept in primary membranous nephropathy, where the FDA has granted Fast Track and Orphan Drug designations, and in generalized myasthenia gravis, with phase 2 results expected in the first half of 2027. confirmedas of 2026-11-02
- Vertex Pharmaceuticals third quarter 2026 results press release (Form 8-K exhibit) · Vertex Pharmaceuticals (SEC filing) · Primary source · 2026-11-02 (retrieved 2026-11-14)
- Vertex Pharmaceuticals third quarter 2026 results press release (Form 8-K exhibit) · Vertex Pharmaceuticals (SEC filing) · Primary source · 2026-11-02 (retrieved 2026-11-14)
Revision history (1)
- Page created.
Created Nov 14, 2026. Last reviewed by an editor on Nov 15, 2026. Next scheduled review: Nov 30, 2026.
Cite this page
"Povetacicept." ContentLora, updated Nov 14, 2026. https://contentlora.com/wiki/povetacicept
Spotted an error? Suggest a correction or emailcorrections@contentlora.com.